BR112021009381A8 - Compostos espiro heterocíclicos como inibidores de receptor de am2 - Google Patents

Compostos espiro heterocíclicos como inibidores de receptor de am2

Info

Publication number
BR112021009381A8
BR112021009381A8 BR112021009381A BR112021009381A BR112021009381A8 BR 112021009381 A8 BR112021009381 A8 BR 112021009381A8 BR 112021009381 A BR112021009381 A BR 112021009381A BR 112021009381 A BR112021009381 A BR 112021009381A BR 112021009381 A8 BR112021009381 A8 BR 112021009381A8
Authority
BR
Brazil
Prior art keywords
compounds
heterocyclic compounds
receptor inhibitors
spiro heterocyclic
inhibitors
Prior art date
Application number
BR112021009381A
Other languages
English (en)
Other versions
BR112021009381A2 (pt
Inventor
Gareth Richards
Jean-Olivier Zirimwabagabo
P A Harrity Josephy
Richard Gibson Karl
J Tozer Matthew
Alan Glossop Paul
Alan Porter Roderick
M Skerry Timothy
Original Assignee
Univ Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sheffield filed Critical Univ Sheffield
Publication of BR112021009381A2 publication Critical patent/BR112021009381A2/pt
Publication of BR112021009381A8 publication Critical patent/BR112021009381A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

espiro-compostos heterocíclicos como inibidores de receptor de am2. trata-se de compostos da fórmula (i) e de sais farmaceuticamente aceitáveis dos mesmos: em que het, r1, r2, r3, r4, r5, l, l1, x1, x2, x3 e q são conforme definido no presente documento. os compostos são inibidores de receptor de adrenomedulina de subtipo 2 (am2). também são revelados os compostos para uso no tratamento de doenças moduladas por am2, incluindo doenças proliferativas, como câncer; composições farmacêuticas que compreendem os compostos; métodos para preparar os compostos; e intermediários úteis na preparação dos compostos.
BR112021009381A 2018-11-15 2019-11-15 Compostos espiro heterocíclicos como inibidores de receptor de am2 BR112021009381A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1818651.0A GB201818651D0 (en) 2018-11-15 2018-11-15 Compounds
GB1818651.0 2018-11-15
PCT/GB2019/053236 WO2020099882A1 (en) 2018-11-15 2019-11-15 Heterocyclic spiro-compounds as am2 receptor inhibitors

Publications (2)

Publication Number Publication Date
BR112021009381A2 BR112021009381A2 (pt) 2021-08-10
BR112021009381A8 true BR112021009381A8 (pt) 2022-03-22

Family

ID=64740129

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021009381A BR112021009381A8 (pt) 2018-11-15 2019-11-15 Compostos espiro heterocíclicos como inibidores de receptor de am2

Country Status (11)

Country Link
US (1) US20220023281A1 (pt)
EP (1) EP3880679A1 (pt)
JP (1) JP2022507561A (pt)
KR (1) KR20210102261A (pt)
CN (1) CN113227091A (pt)
AU (1) AU2019380715A1 (pt)
BR (1) BR112021009381A8 (pt)
CA (1) CA3119882A1 (pt)
GB (1) GB201818651D0 (pt)
SG (1) SG11202104857PA (pt)
WO (1) WO2020099882A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
GB201818649D0 (en) * 2018-11-15 2019-01-02 Univ Sheffield Compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004273057C1 (en) * 2003-09-08 2011-06-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
JP2008512459A (ja) * 2004-09-09 2008-04-24 メルク エンド カムパニー インコーポレーテッド アリールスピロラクタムｃｇｒｐ受容体拮抗薬
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
CA2683581A1 (en) * 2007-04-11 2008-10-23 Merck & Co., Inc. Cgrp receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
WO2009034028A2 (de) * 2007-09-07 2009-03-19 Boehringer Ingelheim International Gmbh Neue verbindungen
KR20090033583A (ko) * 2007-10-01 2009-04-06 주식회사 엘지생명과학 글라이신 아릴 아마이드를 포함하는 신규한베타-세크리타제 저해용 화합물
AU2008337286B2 (en) 2007-12-19 2014-08-07 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
WO2010107809A2 (en) * 2009-03-17 2010-09-23 Forest Laboratories Holdings Limited Methods for preparing dpp-iv inhibitor compounds
EP2531502B1 (en) 2010-02-01 2014-04-02 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
JP2014148491A (ja) * 2013-02-04 2014-08-21 Kowa Company Ltd Ｔｌｒ阻害作用を有するチアゾール誘導体
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
CN107567438B (zh) * 2015-03-03 2021-06-29 拜尔哈文制药股份有限公司 利鲁唑前药及其用途
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
GB201818649D0 (en) * 2018-11-15 2019-01-02 Univ Sheffield Compounds

Also Published As

Publication number Publication date
EP3880679A1 (en) 2021-09-22
KR20210102261A (ko) 2021-08-19
AU2019380715A1 (en) 2021-06-10
GB201818651D0 (en) 2019-01-02
CA3119882A1 (en) 2020-05-22
BR112021009381A2 (pt) 2021-08-10
JP2022507561A (ja) 2022-01-18
WO2020099882A1 (en) 2020-05-22
CN113227091A (zh) 2021-08-06
US20220023281A1 (en) 2022-01-27
SG11202104857PA (en) 2021-06-29

Similar Documents

Publication Publication Date Title
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
BR112021024674A2 (pt) Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
BR112016016844A2 (pt) Compostos heterocíclicos
BR112016006651A8 (pt) derivados de quinolizina substituídos, composição farmacêutica que os compreede e uso dos mesmos.
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
AR102204A1 (es) Compuestos derivados de amino-alquilbenzotiazepinas
BR112017012755A2 (pt) compostos de heteroarila de anel fundido e seu uso como inibidores de trk
BR112018015419A2 (pt) degradantes seletivos de receptor de estrogênio e os usos dos mesmos
BR112016028835A2 (pt) derivados de auristatina e conjugados dos mesmos
BR112017027414A2 (pt) Derivados hidroxiéster, processo para prepará- los e composições farmacêuticas os contendo
BR112016015365A8 (pt) composto, composição farmacêutica e uso de um composto
CR20150454A (es) Compuestos amida para el tratamiento de vih
BR112017011941A2 (pt) compostos 5-amino-6h-tiazol [4,5-d] pirimidina-2,7-diona substituídos 3 para o tratamento e profilaxia de infecção viral
BR112013006360A2 (pt) derivados de pirazina como bloqueadores de enac
BR112012030820A8 (pt) Derivados de aminopirimidina como moduladores de lrrk2, seu uso e composição que os compreende
BR112014011850A2 (pt) derivados de aminopirimidina como moduladores de lrrk2
BR112015023760A2 (pt) compostos e composições terapêuticas
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
PE20151601A1 (es) Compuestos novedosos de pirimidina y piridina y su uso
BR112018013251A2 (pt) compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase
BR112014027117A8 (pt) Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
BR112015016325A2 (pt) Composto, composição farmacêutica, e, usos de uma composição, composto, pró-droga ou sal farmaceuticamente aceitável do mesmo
BR112017001334A2 (pt) compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]